Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 347

1.

Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies.

Horváth A, Andersen I, Junker K, Lyck Fogh-Schultz B, Holm Nielsen E, Gizurarson S, Andersen O, Kármán J, Rajnavölgyi E, Erdei A, Svehag SE.

Antiviral Res. 2001 Oct;52(1):43-53.

PMID:
11530187
2.

Serum amyloid P component binds to influenza A virus haemagglutinin and inhibits the virus infection in vitro.

Andersen O, Vilsgaard Ravn K, Juul Sørensen I, Jonson G, Holm Nielsen E, Svehag SE.

Scand J Immunol. 1997 Oct;46(4):331-7.

4.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

5.

Serum amyloid P is a sialylated glycoprotein inhibitor of influenza A viruses.

Job ER, Bottazzi B, Gilbertson B, Edenborough KM, Brown LE, Mantovani A, Brooks AG, Reading PC.

PLoS One. 2013;8(3):e59623. doi: 10.1371/journal.pone.0059623. Epub 2013 Mar 27.

7.

Natural influenza A virus infection of mice elicits strong antibody response to HA2 glycopolypeptide.

Kostolanský F, Mucha V, Slováková R, Varecková E.

Acta Virol. 2002;46(4):229-36.

PMID:
12693859
8.
9.

Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection.

Gocník M, Fislová T, Mucha V, Sládková T, Russ G, Kostolansky F, Varecková E.

J Gen Virol. 2008 Apr;89(Pt 4):958-67. doi: 10.1099/vir.0.83524-0.

PMID:
18343837
11.

Identification of a novel HA conformational change inhibitor of human influenza virus.

Yoshimoto J, Kakui M, Iwasaki H, Fujiwara T, Sugimoto H, Hattori N.

Arch Virol. 1999;144(5):865-78.

PMID:
10416371
12.

In vivo antiinfluenza virus activity of Kampo medicine Sho-seiryu-to through mucosal immune system.

Yamada H, Nagai T.

Methods Find Exp Clin Pharmacol. 1998 Apr;20(3):185-92. Review.

PMID:
9646280
13.

Isolation and characterization of conglutinin as an influenza A virus inhibitor.

Wakamiya N, Okuno Y, Sasao F, Ueda S, Yoshimatsu K, Naiki M, Kurimura T.

Biochem Biophys Res Commun. 1992 Sep 30;187(3):1270-8.

PMID:
1417803
14.

A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model.

Horimoto T, Takada A, Iwatsuki-Horimoto K, Kawaoka Y.

Vaccine. 2004 Jun 2;22(17-18):2244-7.

PMID:
15149783
15.

[Comparison of in vitro and in vivo methods of evaluation of the efficacy of influenza virus hemagglutinin inhibitors].

Goncharova EP, Bylychev LE, Rak SV, P'iankova OG, Poryvaev VD, Ryzhikov AB.

Zh Mikrobiol Epidemiol Immunobiol. 2006 Jul-Aug;(5):39-46. Russian.

PMID:
16981492
17.

Effects of TheraMax on influenza virus infections in cell culture and in mice.

Smee DF, Hurst BL, Wong MH.

Antivir Chem Chemother. 2011 Jul 4;21(6):231-7. doi: 10.3851/IMP1744.

PMID:
21730370
18.

In vitro and in vivo influenza virus-inhibitory effects of viramidine.

Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF.

Antiviral Res. 2005 Oct;68(1):10-7.

PMID:
16087250
19.

Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.

Isaka M, Zhao Y, Nobusawa E, Nakajima S, Nakajima K, Yasuda Y, Matsui H, Hasegawa T, Maeyama J, Morokuma K, Ohkuma K, Tochikubo K.

Microbiol Immunol. 2008 Feb;52(2):55-63. doi: 10.1111/j.1348-0421.2008.00010.x.

20.

A unique phosphatidylinositol bearing a novel branched-chain fatty acid from Rhodococcus equi binds to influenza virus hemagglutinin and inhibits the infection of cells.

Guo CT, Ohta S, Yoshimoto A, Nakata K, Shortridge KF, Takahashi T, Suzuki T, Miyamoto D, Jwa Hidari KI, Suzuki Y.

J Biochem. 2001 Sep;130(3):377-84.

Supplemental Content

Support Center